PAMELA NJIRU: Open Payments
NPI 1245905819 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,026 in 41 payments from 9 companies in 2025. Trend: 2023 $870 · 2024 $1,022 · 2025 $1,026
Food & beverage: $1,026
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $303 |
| Novo Nordisk Inc | 9 | $198 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $160 |
| AstraZeneca Pharmaceuticals LP | 6 | $106 |
| Exact Sciences Corporation | 3 | $77 |
| Amgen Inc. | 3 | $72 |
| Lilly USA, LLC | 3 | $58 |
| Astellas Pharma US Inc | 1 | $28 |
| Dexcom, Inc. | 1 | $25 |
Products named: CAPLYTA, Kerendia, Rybelsus, AIRSUPRA, Cologuard Collection Kit, OTEZLA, Ozempic, MOUNJARO.
Industry payments across NV — which companies pay providers there.
